417 drug hospitals are not sold! Mainly because of this reason

"
Pharmaceutical Network Industry Dynamic" Recently, Shandong Province Public Resources Trading Center issued a notice, 48 products to withdraw the network, 369 drugs suspended trading, a total of 417 drugs stopped tradingAccording to combing, the withdrawal of the network of 48 drugs, 32 for the adoption of consistency evaluation drugs, 1 for the import of original research drugs, 1 for the new registration of chemical drugs approved generic drugs, the remaining 15 are not listed in the list of drugs concentrated, did not have a consistency evaluationnotable, 233 of the 369 drugs suspended were suspended because of the number of overrated products reached three or morein fact, the current consistency evaluation has entered the harvest period, many varieties piled up over the evaluationAccording to incomplete statistics, as of now, 882 generic products have passed or treated as if they were consistent lying, 167 product regulations have been evaluated by more than two, 88 product regulations have been evaluated by more than 3In this regard, the industry believes that, with more and more over-rated varieties of three, the competition between enterprises will be extremely fierceIn particular, pharmaceutical companies that do not have the capacity to afford consistency evaluation will also face increasing pressurein fact, since the National Health and Health Administration, together with the relevant departments, formulated the Opinions on Improving the National Basic Drug System, clearly proposed to pay more attention to the linkage with the quality and efficacy consistency evaluation of generic drugs, emphasizing that the procedure will be through the consistency evaluation of drug varieties priority into the basic drug catalog, gradually put out the list of generic drugs that have not passed the consistency evaluation, the national consistency evaluation of drugs has entered a accelerated phaseit is understood that since this year, Jiangsu, Shenzhen, Beijing and other places have issued the drug has not been the consistency evaluation of the relevant notice of suspension of procurementFor example, on April 17, the Jiangsu Provincial Public Resources Trading Center issued a notice on the public suspension of procurement for drugs that failed to evaluate the quality and efficacy of generic drugsAmong them, the provincial suspended procurement of 152 drugs, including amoxicillin capsules, omeprazole intestinal capsules, oxalic acid Essipriattablet tablets, meloxikang tablets, bicarbonate, cephalosporine capsules, left ethyl lacitan tablets and so onon the same day, Shenzhen Pharmaceutical Trading Platform suspended the purchase of 8 drugs that had not been evaluated for consistency, involving Atorvastatin calcium tablets, benzodiazepine tablets, amoxicillin capsules, acetaminophen tablets, methazole tablets, and pyrapamine tabletsApril 13, the Beijing Municipal Pharmaceutical Collection and Collection Service Center also issued the "Notice on the suspension of the national collection of some of the product procurement function simply failed to pass the consistency evaluation", 843 drugs were suspended on the internetApril 10, Shanghai issued a notice, clearly put forward the same variety over consistency evaluation of 3 in Shanghai Sunshine procurement platform hanging on the network of the unrated varieties, no longer medical insurance settlement, directly stop reimbursementin short, the current suspension of drug procurement can be said to be the industry has been a normal situationIn addition to drugs because of the lack of consistency evaluation was eliminated, due to the collection of unselected, not involved in price linkage, long-term no transaction records and other reasons are also often dischargedto this, the industry believes that pharmaceutical companies should try to pass consistency evaluation, but also to accelerate the enrichment of their product lines, adjust the research and development track and other ways to strengthen the competitiveness of enterprises and anti-risk capabilities.